Tafenoquine Combinations for Improved Radical Cure Efficacy of Plasmodium Vivax
ClinicalTrials.gov Studies
Summary
NIH registered ClinicalTrials.gov Study NCT07533136, a Phase 4 trial evaluating tafenoquine-based combination therapies for radical cure of uncomplicated Plasmodium vivax malaria in Thai adults. The study compares dihydroartemisinin-piperaquine or artemether-lumefantrine with tafenoquine against chloroquine plus tafenoquine over a 6-month follow-up period to assess recurrence prevention efficacy.
What changed
NIH has registered a new clinical trial on ClinicalTrials.gov. Study NCT07533136 will enroll adult subjects with uncomplicated P. vivax mono-infection in Thailand to compare the therapeutic efficacy of tafenoquine combined with either dihydroartemisinin-piperaquine or artemether-lumefantrine against the standard chloroquine plus tafenoquine regimen over a 6-month observation period.
Affected parties include pharmaceutical companies, clinical investigators, and healthcare providers involved in malaria treatment research. The trial registration establishes a protocol record for evaluating whether alternative combination therapies can improve radical cure outcomes for vivax malaria, potentially informing treatment guidelines in malaria-endemic regions.
Archived snapshot
Apr 16, 2026GovPing captured this document from the original source. If the source has since changed or been removed, this is the text as it existed at that time.
Tafenoquine Combinations for Improved Radical Cure Efficacy of Plasmodium Vivax
N/A NCT07533136 Kind: NA Apr 16, 2026
Abstract
This study is to conduct a clinical trial of tafenoquine combinations to compare the rates of therapeutic efficacy of dihydroartemisinin-piperaquine or artemether-lumefantrine with tafenoquine to chloroquine plus tafenoquine in preventing recurrence of Plasmodium vivax over a 6-month period in adult subjects with uncomplicated P. vivax infection living in Thailand.
Conditions: Uncomplicated P. Vivax Mono-infection
Interventions: Tafenoquine (TQ), Chloroquine (CQ), Dihydroartemisinin-piperaquine (DHA-PPQ), Artemether-lumefantrine (AL)
Related changes
Get daily alerts for ClinicalTrials.gov Studies
Daily digest delivered to your inbox.
Free. Unsubscribe anytime.
Source
About this page
Every important government, regulator, and court update from around the world. One place. Real-time. Free. Our mission
Source document text, dates, docket IDs, and authority are extracted directly from NIH.
The summary, classification, recommended actions, deadlines, and penalty information are AI-generated from the original text and may contain errors. Always verify against the source document.
Classification
Who this affects
Taxonomy
Browse Categories
Get alerts for this source
We'll email you when ClinicalTrials.gov Studies publishes new changes.
Subscribed!
Optional. Filters your digest to exactly the updates that matter to you.